DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Viralytics
Viralytics
United States Securities and Exchange Commission Form
News Release
Merck & Co., Inc
Merck & Co., Inc
2018 Medicines in Development for Skin Diseases
Merck & Co., Inc
Viralytics Presents New CAVATAK® Data at the 11Th International Oncolytic Virus Conference
Merck & Co., Inc
News Release
Merck & Co., Inc
Viral Targeting of Non-Muscle Invasive Bladder Cancer and Priming of Anti-Tumour Immunity Following Intravesical Coxsackievirus A21
Merck & Co., Inc
Immutep (IMM) 22 April 2020 Speculative Investment
Merck & Co., Inc
Paradigm Biopharmaceuticals Ltd Implied Return 110% Marc Sinatra +61 3 9200 7050 I
[email protected]
Repurposing with Purpose 30 November, 2015
Using the Cold Virus to Kill Cancer Cells
Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’S Leading Immuno- Oncology Pipeline
Merck & Co., Inc. Form 10-K Annual Report Filed 2019-02-27
Top View
General Shareholders Meeting 2018 Company Presentation
Viralytics Annual Report and Full Year Financial Results
Delayed Immune-Related Events (DIRE) After Discontinuation of Immunotherapy: Diagnostic Hazard of Autoimmunity at a Distance Marcus A
2018 Clarivate/Cortellis Year in Review
For Personal Use Only
Viralytics FY17 Results
Luxturna EU Approval: Novartis' Lessons for Gene Therapy Success
Merck News Release
Updated-Final List of Pharma Product Patents During 2005-06 to 2009-10
RS PDF Biotech Data
COMPASS Report
News Release
For Personal Use Only Use Personal for and YERVOY (Ipilimumab) Is Well Tolerated and Has Activity in Advanced
Merck & Co Makes Biggest Oncolytic Virus Bet Since Amgen in 2011
Second-Quarter 2018 Financial Results
Key Events & Trends
Paradigm Biopharma
Adjuvant Nivolumab for Stage III/IV Melanoma: Evaluation of Safety Outcomes and Association with Recurrence-Free Survival
Merck & Co., Inc
A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels